Athira Pharma, Inc. financial data

Symbol
ATHA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
18706 North Creek Parkway, Suite 104, Bothell, WA
Fiscal year end
December 31
Former names
M3 Biotechnology, Inc. (to 1/23/2019)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 399 % -44.9%
Debt-to-equity 33.2 % +116%
Return On Equity -133 % -91.8%
Return On Assets -99.5 % -66.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39M shares +1.86%
Common Stock, Shares, Outstanding 39M shares +2.28%
Entity Public Float 86M USD -10.7%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.5M shares +1.21%
Weighted Average Number of Shares Outstanding, Diluted 38.5M shares +1.21%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 70.7M USD -24.6%
General and Administrative Expense 26.1M USD -21.7%
Costs and Expenses 101M USD -19.6%
Operating Income (Loss) -101M USD +19.6%
Net Income (Loss) Attributable to Parent -96.9M USD +17.6%
Earnings Per Share, Basic -2.52 USD/shares +18.4%
Earnings Per Share, Diluted -2.52 USD/shares +18.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.4M USD -46.5%
Assets, Current 54.8M USD -64.6%
Property, Plant and Equipment, Net 2.44M USD -27.9%
Operating Lease, Right-of-Use Asset 808K USD -23%
Other Assets, Noncurrent 55K USD -87.7%
Assets 58.8M USD -63.3%
Accounts Payable, Current 319K USD +147%
Employee-related Liabilities, Current 2.99M USD -34.2%
Accrued Liabilities, Current 12.4M USD -32.4%
Liabilities, Current 13.1M USD -54.5%
Operating Lease, Liability, Noncurrent 803K USD -34%
Liabilities 13.9M USD -53.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -406M USD -31.4%
Stockholders' Equity Attributable to Parent 44.8M USD -65.6%
Liabilities and Equity 58.8M USD -63.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.8M USD +1.49%
Net Cash Provided by (Used in) Financing Activities 99K USD -52.9%
Net Cash Provided by (Used in) Investing Activities 13M USD -63.3%
Common Stock, Shares Authorized 900M shares 0%
Common Stock, Shares, Issued 39M shares +2.28%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.8M USD -235%
Deferred Tax Assets, Valuation Allowance 91.9M USD +29.1%
Deferred Tax Assets, Gross 92.2M USD +28.5%
Operating Lease, Liability 1.22M USD -23.2%
Depreciation 970K USD +0.1%
Payments to Acquire Property, Plant, and Equipment 5K USD -97.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -96.6M USD +16.8%
Lessee, Operating Lease, Liability, to be Paid 1.35M USD -26.2%
Property, Plant and Equipment, Gross 5.74M USD +0.3%
Operating Lease, Liability, Current 414K USD +12.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 509K USD +3.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 494K USD +2.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 132K USD -45.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 509K USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 43.4M USD +38.5%
Unrecognized Tax Benefits 4.12M USD +32.6%
Deferred Tax Assets, Net of Valuation Allowance 25.2M USD +136%
Share-based Payment Arrangement, Expense 11M USD +4.01%